Royalty Report: Drugs, Cancer – Collection: 332237


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 332237

License Grant
Licensor hereby grants to Canadian Licensee and Licensee hereby accepts a non-exclusive license under Licensed Patents during the Term to research, develop, make (and have made), use, sell, offer for sale, and import Licensed Product in the Territory in the Field of Use.  Licensee shall have a right to grant sublicenses.
License Property
Licensed Patents shall mean (a) US Patent Nos. 6,579,520 and 6,569,645, (b) any patents issuing from continuations, divisions, or continuations-in-part from which any of the foregoing claim priority, and (c) invention certificates, substitutions, reissues, reexaminations, extensions, registrations, patent term extensions, supplementary, supplementary protection certificates, renewals and foreign counterparts of any of the foregoing (a) or (b), including without limitation EP 1240325, and CA 2391374.

6,579,520 – IL-17 related mammalian cytokine polypeptides (IL-17E)
6,569,645 – IL-17 homologous polypeptides and therapeutic uses thereof

Licensee Protein means a IL-17E protein for which either (a) the research and/or at least one Clinical Trial was significantly conducted by Licensee either on its own, or together and in
collaboration with a Sublicensee or (b) Licensee and/or its Sublicensees have exclusive marketing rights worldwide.

Field of Use
Field of Use means treatment of human cancer.

IPSCIO Record ID: 289242

License Grant
Licensor hereby grants to Japanese Licensee, under the Licensed Technology, an exclusive, royalty-bearing license, with the right to grant sublicenses, to develop, have developed, make, have made, use, sell, offer for sale and import Licensed Products within the Licensed Field in the Licensee Territory.
License Property
Licensed Product shall mean
          (i)   any Clinical Candidate (as defined in the Collaboration Agreement);
          (ii)  any compound (a) which is identified, developed or discovered by Licensee using Licensed Technology and (b) which acts through activation of the insulin signal transduction pathway for the treatment of diabetes mellitus or insulin resistance in humans; and
          (iii) any compound which is an analog, homolog or chemical modification of a compound described in clause (i) or (ii) and which acts through activation of the insulin signal transduction pathway for the treatment of diabetes mellitus or insulin resistance in humans.

Licensed Technology shall mean the Licensed Patent Rights and the Licensed Know-How.

Licensed Patent Rights shall mean all of (i) Licensors interest in any patents and patent applications (including any divisions, continuations-in-part, reissues, extensions, renewals, supplementary protection certificates and foreign counterparts thereof) covering inventions made in the course of the Research Program (the Research Program Patents) and (ii) other patents and patent applications (including any divisions, continuations-in-part, reissues, extensions, renewals, supplementary protection certificates and foreign counterparts thereof) owned or Controlled by Licensor, but only to the extent such other patents and patent applications are necessary or useful for Licensee for the manufacture, use, sale, offer for sale or import of Licensed Products which are covered by the Research Program Patents.

Field of Use
License is for the development of a Type II diabetes drug.  The molecular fingerprinting is a family of small molecules that have demonstrated they can bind to and activate the insulin receptor to lower blood glucose levels in diabetes patients.

IPSCIO Record ID: 367328

License Grant
Canadian University grants to the Canadian Licensee a worldwide, exclusive license to use and sublicense the Technology, University Improvements and any Joint Improvements and to manufacture, have made, distribute, and sell the Products on the terms and conditions set out in this Agreement.

The license granted under this Agreement is granted only to the Licensee and not to any Affiliated Companies. The Licensee will not cross-license the Technology or any Improvements without the prior written consent of University, which consent will not be unreasonably withheld.

The Licensee will not grant sublicenses of the Technology, University Improvements or any Joint Improvements to Affiliated Companies or other third parties without the prior written consent of University which consent will not be unreasonably withheld.

License Property
The technology relates to Hsp27 antisense and its use in the treatment of cancer.

Technology  means the Patents and all knowledge, know-how and/or technique or techniques invented, developed and/or acquired, before the Effective Date by University or the Licensee relating to, and including, the technology and materials described, as amended from time to time, including, without limitation all related research, data, specifications, instructions, manuals, papers or other related materials of any nature at all, whether written or otherwise, and University’s Confidential Information.
U.S. Provisional filed
April 18, 2003, Serial No.
60/463,952 Hsp27 Antisense to Treat Prostate and other Solid Tumours.

Patents mean collectively the rights in and to any and all inventions which are disclosed in the U.S., Canadian and foreign patents and patent applications identified and all
(i)            counterparts, continuations, divisionals, continuations-in-part, continuing prosecution applications, and requests for continued examinations, extensions, term restorations, renewals, reissues, re-examinations, or substitutions thereof;
(ii)           corresponding international patent applications;
(iii)          corresponding foreign patent applications, including supplementary protection certificates and other administrative protections; and
(iv)          international and foreign counterpart patents resulting therefrom, all of which will be deemed added, from time to time.
U.S. Provisional filed October 2, 2002, Serial
No. 60/415,859 Hsp27 Antisense to Treat Prostate and other Solid Tumours.

Product(s) means goods or services manufactured or provided in connection with the use of all or some of the Technology and/or any Improvements.

Field of Use
Field of use is for the treatment of cancer relating to Hsp27 antisense technology.

IPSCIO Record ID: 275809

License Grant
The Swiss Licensor grants to Licensee and its Affiliates, and Licensee accepts on behalf of itself and its Affiliates, the sole and exclusive right and license under the Licensed Technology and Licensed Patents within the Field throughout the Territory (with the right to grant sublicenses) to develop, manufacture, have manufactured, market, import, use, offer for sale, and sell the Products.
License Property
Licensed Compounds means all forms of protein that have the function or activity of the Interleukin-12 protein, including the Interleukin-12 kDa heterodimer protein, subunits of the Interleukin-12 kDa heterodimer protein, including the 40 kDa homodimer subunit and the 35 kDa homodimer subunit, and combinations of such subunits; all forms of proteins that have the function or activity of the Interleukin-12 receptor; polypeptide fragments and muteins of all of the above; and nucleotides coding for Interleukin-12 receptors.

Licensed Patents means rights under patents and patent applications, as well as corresponding certificates of invention or certificates of protection, substitutes, extensions, supplementary protection certificates, renewals, continuations-in-part, divisions, patents of addition (re-examination or re-issue), in any country of the Territory, which (a) but for this Agreement would be infringed by the developing, making, having made, marketing, importing, using, offering for sale or sale by Licensee, its Affiliates or Sublicensees of Products in the Field and (b) are owned by, or licensed to, Licensor as of the Effective Date or during the Term, to the extent such rights are necessary to develop, make, have made, market, import, use, offer for sale or sell a Product in the Field in the Territory.

Field of Use
Licensee filed an investigational new drug application to begin clinical testing of Levovirin for use in combination with interferon alpha for the treatment of hepatitis C.
Levovirin may have an ability to stimulate an immune response to some viral infections without the anemia associated with ribavirin.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.